Transcripts
The Cigna Group's management answers for the business every quarter. These are the exchanges that explain it best — verbatim, from the call transcripts preserved in Sources. Each link opens the full transcript at that page in a new tab.
Q1 2026 Earnings Call — Q1 FY2026
David Cordani's final call: the leadership handoff, two portfolio exits, and the clearest map of where Cigna's earnings come from. · Open the full transcript →
Where the earnings come from: Specialty & Care ~35%, Pharmacy Benefit Services ~25%, Cigna Healthcare ~40%.
Scott Fidel (Analyst, Goldman Sachs); Brian Evanko (President and Chief Operating Officer): One is our Specialty and Care Services platform, which now represents about 35% of the company's income and is growing 8% to 12% per year, as Ann just referenced earlier. Secondly, our Pharmacy Benefit Services platform also within Evernorth, about 25% of the company's income is going through the transformation that I was alluding to earlier, and we're confident on the long-term durability of that. And then finally, our Cigna Healthcare business, which represents the other 40% of the company's income, which is our high-performing health plan business, underpinned by our flagship U.S. employer business, which has shown a long track record of growing at above market rates.
p. 10 · Read in context →
Guidance philosophy: priced for sustained elevated cost trend; deceleration would be upside, not baseline.
Brian Evanko (President and Chief Operating Officer): As Ann said, we continue to plan for and price for sustained elevated cost trends. On the positive side, they have not accelerated. They remained elevated. So to the extent we do eventually see some deceleration, that offers some upside to our outlook.
p. 14 · Read in context →
Q4 2025 Earnings Call — Q4 FY2025
The FTC settlement resolved and PBM reform passed — management lays out how the rebate-free model actually gets paid, margin profile intact. · Open the full transcript →
The FTC global settlement, framed: $7B in out-of-pocket relief over ten years, resolving insulin litigation and investigations.
David Cordani (Chairman and Chief Executive Officer): The settlement is a comprehensive resolution of all matters brought by the FTC regarding our pharmacy benefits business. It includes the industry-wide insulin lawsuit and ongoing investigations. […] The settlement noted $7 billion in out-of-pocket cost relief over the next ten years for the 100 million customers and patients we serve. The savings will be delivered through lower insulin prices and reduced costs for brand-name medications for consumers at the pharmacy counter.
p. 2 · Read in context →
How the rebate-free model makes money: a delinked per-member/per-script admin fee plus at-risk clinical programs, same profitability.
Scott Fidel (Analyst, Goldman Sachs); Brian Evanko (President and Chief Operating Officer): the core value creators in both our legacy models and our new rebate-free model really remain the same. Think about securing better unit pricing for prescription drugs, administering benefits for plan sponsors, and supporting patients with clinical safety checks and advanced clinical programs. […] So there's two primary ways we get paid in the future in this model. The first is a core admin fee. That'll be per member or per script, delinked from the price of the drug, that'll grow with inflation over time. And then the second category would be for clinical programs and other innovations that we bring to market. And we expect to take risk on this portion of compensation. But in aggregate, as David said earlier, we expect to achieve a comparable level of profitability between the legacy model and the new model, although the sources of profit will evolve as I outlined.
p. 8 · Read in context →
The specialty growth engine: a $400B+ market, 13% script growth, an 8–12% income algorithm, $100B of biosimilar competition by 2030.
Erin Wright (Analyst, Morgan Stanley); Brian Evanko (President and Chief Operating Officer): this is already a $400 billion plus addressable market growing at a high single-digit secular growth rate, and we're really well-positioned to capitalize on that over the longer run. […] the full year we had 13% growth in prescriptions, higher rate of growth in our Medicare book of business, but also strong growth in the commercial employer and the Medicaid portfolio […] We continue to expect long term average annual income growth of 8% to 12% in this business, benefiting from some of these strong secular tailwinds. […] we expect another $100 billion of specialty drug spend to be subject to competition from biosimilars and generics by 2030.
p. 11 · Read in context →
Q3 2025 Earnings Call — Q3 FY2025
Where the rebate-free model was first unveiled: the drug-pricing problem it solves and a three-part framework for modeling the PBM through the transition. · Open the full transcript →
The problem the model targets: generics are 90% of scripts but ~10% of spend; brands are 10% of volume but 88% of spend.
David Cordani (Chairman and CEO): generic drugs now account for 90% of all prescriptions, and on average, they are one-third cheaper than in other countries. […] On the other hand, prices for brand name medications continue to skyrocket, with those drugs that do not have a generic equivalent costing four times as much as the same drug in European markets. […] even though brand name drug medications comprise only 10% of overall pharmaceutical volumes in the United States, they account for 88% of the spend.
p. 2 · Read in context →
The new model, first unveiled: upfront discounts replacing post-purchase rebates, ~30% lower brand cost, standard by 2028.
David Cordani (Chairman and CEO): we've stepped forward with our new simple and transparent model for pharmacy benefit services, which will replace the complex post-purchase rebate process with a simple upfront discount that will enable customers and patients to automatically pay the lowest price at the counter, whether through their benefit or on a cash pay basis and apply their payments to the deductible. […] for Americans and health plans where they pay the full cost of medications, our new model will reduce the cost for a brand name drug prescription on average by 30%. […] Cigna Healthcare will adopt this model 100% for fully insured lives beginning in 2027, and it will become our standard offering broadly for the Cigna Group to the marketplace starting in January 2028.
p. 2 · Read in context →
A framework for the transition: $90B of renewed large-client revenue, temporary 2026–27 investment costs, and a stable core book.
Lisa Gill (Analyst, JPMorgan); Brian Evanko (President and COO): When considering how to model this business going forward, I suggest breaking it into three categories. The first category includes the three major clients we've mentioned, accounting for roughly $90 billion in annual revenue, with the margin profile for 2026 expected to sustain through the decade. […] The second category pertains to the costs associated with transitioning to the new rebate-free model, which will create margin pressures in 2026 and 2027 but should diminish afterward. The third category reflects the fundamental earnings profile from the remainder of our pharmacy benefit services book, which we expect will remain stable in terms of client level earnings contributions, ensuring comparable contributions from our rebate-free model as from our existing solutions.
p. 7 · Read in context →
Guidance philosophy through the pivot: two platforms on-algorithm in 2026, PBS off, enterprise back on-algorithm in 2027.
David Cordani (Chairman and CEO); Justin Lake (Analyst, Wolfe Research): As you think about the building blocks of the capabilities, our CHC are on algorithm in '26, Specialty & Care on algorithm in '26, PBS off algorithm in '26. […] while there are investments that will carry into 2027, it would be reasonable to assume we expect to be back on algorithm for the enterprise level for 2027 with the strength of the franchise.
p. 8 · Read in context →
Q4 2024 Earnings Call — Q4 FY2024
The stop-loss shock, explained: a cost miss and the two-year margin-recovery plan, alongside the post-Brian-Thompson push on transparency. · Open the full transcript →
Management addresses the moment: after the killing of UnitedHealth's Brian Thompson, accelerating transparency and accountability.
David Cordani (CEO): In early December, we all witnessed the tragic murder of Brian Thompson, a leader at the UnitedHealth Group. The past several weeks have further challenged us to listen more intensely to the public narrative about our industry. At the Cigna Group, we are further accelerating improvements and innovations to increase transparency, expand support, and drive even greater accountability.
p. 1 · Read in context →
What stop-loss is and why it missed: employers cap catastrophic-claim risk; high-cost claimants and specialty drugs drove Q4 variability.
Brian Evanko (CFO): stop loss is a unique product within our portfolio where employers limit their risk from unexpected high-cost claims by transferring that risk for medical costs above a specific individual or aggregate employer dollar amount. […] This year, variability was more pronounced in the fourth quarter as we had an increase in the number of high-cost claimants related to cost pressures from the continued acceleration in the prescribing and use of specialty medications, as well as elevated high-acuity surgical activity.
p. 3 · Read in context →
Why the miss is recoverable: stop-loss is only sold integrated with first-dollar coverage; 50%+ of those clients stay 5+ years.
Stephen Baxter (Analyst, Wells Fargo); Brian Evanko (CFO): we don't write standalone stop loss coverage. So our entire book of business reflects an integrated employer offering where we're providing the firstdollar coverage alongside. […] well over 50% of our employer clients who choose our stop loss products have been clients of Cigna Healthcare for five years or more.
p. 6 · Read in context →
Q4 2023 Earnings Call — Q4 FY2023
The portfolio-shaping landmark: exiting Medicare Advantage to double down on capital-light Evernorth services, funded by the Express Scripts payoff. · Open the full transcript →
The track record: 13%+ annualized EPS growth over a decade, every Express Scripts goal met, $27B returned to shareholders.
David Cordani (Chairman and Chief Executive Officer): As a result of our focus, discipline, and sustained execution, over the past decade, we've delivered adjusted EPS growth of more than 13% on an annualized basis. In the five years since our acquisition of Express Scripts, we've achieved or surpassed every goal we established for the combined company. Through 2023, we've grown revenue by over $50 billion and met or exceeded our adjusted EPS objectives each year. And we've returned $27 billion to shareholders through share repurchase as well as attractive dividend payments.
p. 5 · Read in context →
Why exit Medicare Advantage: an attractive market, but capital-intensive and heavily regulated relative to its size in the portfolio.
A.J. Rice (Analyst, UBS); David Cordani (Chairman and Chief Executive Officer): We see it as a win-win and it's a clarification to our strategy within our portfolio. As I noted in my prepared remarks, while we view the market as a attractive growth market, the required capital investment resources focus relative to its size within our portfolio, coupled with the continued elevated regulatory environment, our decision was it was best to enter this transaction.
p. 14 · Read in context →
The strategic pivot: grow government reach through capital-light Evernorth services rather than owning the health plan.
David Cordani (Chairman and Chief Executive Officer): We will continue in a long-term service relationship with HCSC that further expands our proven track record within Evernorth. We see the Evernorth service portfolio as an attractive, capital-light, high-visibility way to grow this portfolio. And as we have in the past, we will maintain very strong discipline for capital deployment, and our 2024 capital deployment priorities are quite clear.
p. 15 · Read in context →
More calls
Q2 2025 Earnings Call — Q2 FY2025 · 14 pages · Mid-2025 read on the stop-loss margin-recovery plan and specialty momentum — the quarter before the rebate-free model was unveiled. · Open →
Q1 2025 Earnings Call — Q1 FY2025 · 15 pages · First quarter after the Medicare divestiture closed and Evanko/Dennison were named to new roles — the reset earnings base and early stop-loss recovery signals. · Open →
Q2 2024 Earnings Call — Q2 FY2024 · 14 pages · Progress on the Medicare Advantage sale to HCSC and the Evernorth specialty and care build-out at mid-2024. · Open →
Q1 2023 Earnings Call — Q1 FY2023 · 40 pages · An early call under the newly renamed Cigna Group for baseline framing of the Evernorth and Cigna Healthcare two-platform model. · Open →
Q4 2021 Earnings Call — Q4 FY2021 · 49 pages · A pandemic-era annual call for fuller strategic framing of the Evernorth build-out and the long-term growth algorithm before the recent portfolio moves. · Open →